Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

BACKGROUND: Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-generation BTKi therapy, acalabrutinib, is unknown. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Sunnia T., Azali, Leylah, Rosen, Lindsay, Zhao, Qiuhong, Wiczer, Tracy, Palettas, Marilly, Gambril, John, Kola-Kehinde, Onaopepo, Ruz, Patrick, Kalathoor, Sujay, Rogers, Kerry, Kittai, Adam, Grever, Michael, Awan, Farrukh, Byrd, John C., Woyach, Jennifer, Bhat, Seema A., Addison, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281099/
https://www.ncbi.nlm.nih.gov/pubmed/35836241
http://dx.doi.org/10.1186/s13045-022-01302-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281099/
https://www.ncbi.nlm.nih.gov/pubmed/35836241
http://dx.doi.org/10.1186/s13045-022-01302-7

Ejemplares similares